Contact
searchSearch
HMP Global
Login

B-Cell Lymphoma Resource Center

Conference Coverage
SEER Analysis Highlights Risk Factors for Advanced DLBCL at Diagnosis
03/27/2026
Grace Taylor, MS, MA
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis...
03/27/2026
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
Conference Coverage
Improving Outcomes in Diffuse Large B-Cell Lymphoma: Molecular Subtypes and Early Response Assessments
12/15/2025
Grace Taylor, MS, MA
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025...
12/15/2025
Journal of Clinical Pathways
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD ...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
From Oncology
News
Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma
01/30/2024
Grace Taylor, MS, MA
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and...
01/30/2024
Journal of Clinical Pathways
Conference Coverage
Incidence and Survival Outcomes of Diffuse Large B-Cell Lymphoma in Adolescents and Young Adults
12/07/2023
Grace Taylor, MS, MA
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted...
12/07/2023
Journal of Clinical Pathways
News
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel and Tisagenlecleucel for Third-Line or Later Treatment for R/R DLBCL
09/12/2023
Grace Taylor, MS, MA
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of...
09/12/2023
Journal of Clinical Pathways
Stephen Edge, MD.
Videos
Clinical Pathways in Practice at Roswell Park Cancer Center
09/05/2023
Stephen Edge, MD
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president...
09/05/2023
Journal of Clinical Pathways
News
NCCN Updates Clinical Practice Guidelines for B-Cell Lymphomas
08/30/2023
Grace Taylor, MS, MA
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated...
08/30/2023
Journal of Clinical Pathways
News
The Impact of Demographic Factors on Time to Diagnosis for Patients With Diffuse Large B-Cell Lymphoma
08/03/2023
Grace Taylor, MS, MA
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how...
08/03/2023
Journal of Clinical Pathways
Manali Kamdar Headshot
Videos
Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma
07/19/2023
Manali Kamdar, MD
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of...
07/19/2023
Journal of Clinical Pathways

Expert Insights

Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD ...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
Stephen Edge, MD.
Videos
Clinical Pathways in Practice at Roswell Park Cancer Center
09/05/2023
Stephen Edge, MD
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president...
09/05/2023
Journal of Clinical Pathways
Manali Kamdar Headshot
Videos
Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma
07/19/2023
Manali Kamdar, MD
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of...
07/19/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
The Benefits of Incorporating Radiation Therapy Into the Treatment of Primary CNS Lymphoma
01/05/2023
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting,...
01/05/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
Retrospective Analysis of Survival Outcomes Following Treatment for Primary CNS Lymphoma
01/05/2023
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS,...
01/05/2023
Journal of Clinical Pathways
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
Alice J Chen, PhD
Videos
The Value of Reducing CAR-T Treatment Wait Times Among Patients With Diffuse Large B-cell Lymphoma
10/04/2022
Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.
Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.
Alice J Chen, PhD, found that...
10/04/2022
Journal of Clinical Pathways
Patrick Bliven, MD
Videos
Patterns of Therapy Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
08/03/2022
Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...
Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...
Patrick Bliven, MD, discusses...
08/03/2022
Journal of Clinical Pathways
Peter Riedell, MD
Videos
Real-World Safety, Efficacy, and Utilization of Axicabtagene Ciloleucel and Tisagenlecleucel for B-Cell Lymphomas
01/21/2022
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses...
01/21/2022
Journal of Clinical Pathways
Patrick Connor Johnson, MD
Videos
Physician Survey Reveals Key Attributes for Third-Line Treatment Selection for DLBCL
10/18/2021
Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.
Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.
Patrick Connor Johnson, MD,...
10/18/2021
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part II
05/26/2026
Mark A. Socinski, MD
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part I
05/21/2026
Mark A. Socinski, MD
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this...
05/21/2026
Journal of Clinical Pathways
Olivia Lynch
Interview
Where Access Breaks Down: Uncovering Persistent Disparities in Early-Stage Lung Cancer Treatment
04/21/2026
Olivia Lynch, MD, MPH
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research...
04/21/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways

Newsfeed

News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
News
Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma
01/30/2024
Grace Taylor, MS, MA
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and...
01/30/2024
Journal of Clinical Pathways
News
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel and Tisagenlecleucel for Third-Line or Later Treatment for R/R DLBCL
09/12/2023
Grace Taylor, MS, MA
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of...
09/12/2023
Journal of Clinical Pathways
News
NCCN Updates Clinical Practice Guidelines for B-Cell Lymphomas
08/30/2023
Grace Taylor, MS, MA
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated...
08/30/2023
Journal of Clinical Pathways
News
The Impact of Demographic Factors on Time to Diagnosis for Patients With Diffuse Large B-Cell Lymphoma
08/03/2023
Grace Taylor, MS, MA
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how...
08/03/2023
Journal of Clinical Pathways
News
Analysis of Racial Disparities in Cancer-Specific Survival Rates of Patients with Diffuse Large B-Cell Lymphoma
07/06/2023
Grace Taylor, MS, MA
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee,...
07/06/2023
Journal of Clinical Pathways
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways
News
Evolving Treatment Patterns in HCC Reflect Expanding Role of Immunotherapy
05/27/2026
Rebecca Amrick
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving...
05/27/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Guideline-Based Pathways Could Streamline Prior Authorization Processes
05/21/2026
Rebecca Amrick
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have...
05/21/2026
Journal of Clinical Pathways
News
Higher Radon Levels Connected to Increased Risk of Ovarian Cancer in Postmenopausal Women
05/21/2026
Rebecca Amrick
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds...
05/21/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
High-Risk Individuals Delay Lung Cancer Screenings Until Eligible Despite Expanded Medicare Access
05/18/2026
Rebecca Amrick
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s...
05/18/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
HCC Incidence Higher in Rural Populations Due to Changing Risk Factors and Access Barriers
05/15/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC)...
05/15/2026
Journal of Clinical Pathways
News
A New Clinic in Minneapolis is Expected to Expand Health Care Access to Low-Income Populations
05/12/2026
Rebecca Amrick
A new clinic in Minnesota has recently opened to expand care access and treat low-income populations in Southside Minneapolis.
A new clinic in Minnesota has recently opened to expand care access and treat low-income populations in Southside Minneapolis.
A new clinic in Minnesota has...
05/12/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: HCRU and Costs With CAR-T Therapy vs Transplantation for DLCBL
04/08/2021
04/08/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use